{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Edwards Lifesciences Corp.
Edwards Lifesciences Hits Day High with Strong 3.21% Intraday Surge
Edwards Lifesciences Corp. has experienced significant activity, outperforming the S&P 500 in both short-term and long-term metrics. The company maintains a strong return on equity and a low debt-to-equity ratio, indicating solid financial health as it competes in the pharmaceuticals and biotechnology sectors.
Edwards Lifesciences Hits Day High with Strong 3% Intraday Surge
Edwards Lifesciences Corp. demonstrated strong market performance, achieving an intraday high and outperforming the S&P 500 over the past week and year. With a market capitalization of approximately USD 47.65 billion, the company exhibits high management efficiency and a solid financial position, reflected in its return on equity and low debt-to-equity ratio.
Edwards Lifesciences Hits Day High with Strong 3.28% Intraday Surge
Edwards Lifesciences Corp. saw a significant stock price increase on February 24, 2026, outperforming the S&P 500. Over the past week, the stock rose notably, although it experienced a slight decline over the month. The company maintains strong financial metrics, including a high return on equity and low debt-to-equity ratio.
Edwards Lifesciences Opens with 3.2% Gain, Outpacing S&P 500's 0.69% Increase
Edwards Lifesciences Corp. opened with a notable gain, outperforming the S&P 500. Despite a recent monthly decline, the company showcases strong financial metrics, including a high return on equity and low debt-to-equity ratio. Technical indicators suggest a mildly bullish trend, with a positive annual return despite slight profit decreases.
Edwards Lifesciences Hits Day High with Strong 3.33% Intraday Surge
Edwards Lifesciences Corp. has demonstrated notable stock activity, reaching an intraday high and outperforming the S&P 500 over the past week. Despite recent fluctuations, the company maintains a strong market position in the Pharmaceuticals and Biotechnology sector, supported by high management efficiency and a stable financial structure.
Edwards Lifesciences Corp. Hits New 52-Week High at $87.09
Edwards Lifesciences Corp. achieved a new 52-week high of USD 87.09 on October 31, 2025, despite a one-year performance decline. With a market cap of USD 48,455 million, the company shows strong financial metrics, including a P/E ratio of 30.00 and a return on equity of 14.74%.
Edwards Lifesciences Corp. Hits New 52-Week High at $84.66
Edwards Lifesciences Corp. achieved a new 52-week high of USD 84.66 on October 29, 2025, despite a one-year performance decline of 3.96%. With a market cap of USD 48,455 million, the company has a P/E ratio of 30.00 and a return on equity of 14.74%.
Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators
Edwards Lifesciences Corp. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $80.82, reflecting a notable increase. Technical indicators show mixed performance, with varying trends across different timeframes. The company's returns have lagged behind the S&P 500 over longer periods.
Is Edwards Lifesciences Corp. technically bullish or bearish?
As of October 24, 2025, Edwards Lifesciences Corp. shows a mildly bullish trend overall, despite mixed signals from various indicators, with a 1.93% return over the past month, underperforming the S&P 500's 2.32%.
Is Edwards Lifesciences Corp. technically bullish or bearish?
As of October 24, 2025, Edwards Lifesciences Corp. shows a mildly bullish trend, but mixed indicators and underperformance against the S&P 500 suggest caution, with a year-to-date return of 2.80% compared to the S&P's 15.47%.
Is Edwards Lifesciences Corp. technically bullish or bearish?
As of October 24, 2025, Edwards Lifesciences Corp. shows a mildly bullish trend with mixed signals from indicators, having returned 1.96% over the past week, but caution is advised due to its underperformance compared to the S&P 500 year-to-date.
Is Edwards Lifesciences Corp. technically bullish or bearish?
As of September 3, 2025, Edwards Lifesciences Corp. shows a mildly bullish trend, with mixed indicators across daily, weekly, and monthly metrics, while underperforming the S&P 500 in both short-term and long-term returns.
Is Edwards Lifesciences Corp. overvalued or undervalued?
As of July 24, 2025, Edwards Lifesciences Corp. is considered overvalued with a P/E ratio of 30 and has underperformed the S&P 500, returning -20.14% over three years compared to the index's 70.41% gain.
Is Edwards Lifesciences Corp. overvalued or undervalued?
As of July 15, 2024, Edwards Lifesciences Corp. is fairly valued with a P/E ratio of 30, slightly above the industry average, but has underperformed with a -17.14% return over the past year, raising caution for potential investors.
Is Edwards Lifesciences Corp. technically bullish or bearish?
As of June 10, 2025, the trend is mildly bullish, supported by bullish weekly MACD and daily moving averages, but mixed signals from Bollinger Bands and KST indicate a cautious outlook.
Who are in the management team of Edwards Lifesciences Corp.?
As of March 2022, the management team of Edwards Lifesciences Corp. includes Chairman and CEO Michael Mussallem, Lead Independent Director Martha Marsh, Directors Paul LaViolette and Ramona Sequeira, and Independent Directors Kieran Gallahue and William Link. They oversee the company's strategic direction and operations.
What does Edwards Lifesciences Corp. do?
Edwards Lifesciences Corporation manufactures heart valve systems and repair products, with net sales of $1.413 billion and a market cap of approximately $44.23 billion as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and has a P/E ratio of 30.00.
How big is Edwards Lifesciences Corp.?
As of Jun 18, Edwards Lifesciences Corp. has a market capitalization of $44.23 billion, with net sales of $5.54 billion and a net profit of $1.44 billion for the latest four quarters. The balance sheet shows shareholder's funds of $10.00 billion and total assets of $13.06 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
